J&J loses trial over claims linking cancer to asbestos in talc

Johnson & Johnson suffered its first trial loss in a lawsuit claiming its talc-based products including Johnson’s Baby Powder contain cancer-causing asbestos, with a New Jersey jury on Thursday ordering J&J and another company to pay $37 million in damages.

The verdict of liability in Middlesex County Superior Court in New Brunswick came as J&J fights thousands of cases claiming its talc products can also cause ovarian cancer. The jury found J&J and another company liable after more than two months of trial.

The lawsuit was brought by New Jersey resident Stephen Lanzo, who said he developed mesothelioma after inhaling dust that was generated through his regular use of J&J talc powder products since his birth in 1972.

Mesothelioma is a deadly form of cancer closely associated with exposure to asbestos. It affects the delicate tissue that lines body cavities, most often around the lungs, but also in the abdomen and elsewhere.

The jury awarded Lanzo $30 million and his wife $7 million in compensatory damages. It found J&J was responsible for 70 percent of the damages and said a unit of France-based Imerys SA , its talc supplier, was responsible for 30 percent.

The jury will return on Tuesday for further proceedings to determine whether to award punitive damages, according to an online broadcast of the trial by Courtroom View Network.

J&J denied the allegations and says Johnson’s Baby Powder does not contain asbestos or cause cancer.

J&J in a statement said it was disappointed but would withhold further comment until the trial’s completion. Gwen Myers, an Imerys spokeswoman, said Imerys plans to appeal and is confident talc did not cause Lanzo’s cancer.

The Lanzos did not respond to requests for comment.

J&J, based in New Brunswick, New Jersey, faces talc-related lawsuits by 6,610 plaintiffs nationally, largely based on claims it failed to warn women about the risk of developing ovarian cancer by using its products for feminine hygiene.

In five trials in Missouri involving ovarian cancer lawsuits, juries found J&J liable four times and awarded the plaintiffs a total of $307 million. In California, a jury awarded a now-deceased woman $417 million.

But in October, a Missouri appellate court threw out the first verdict there for $72 million and a California judge tossed the $417 million verdict. J&J is seeking to reverse the other verdicts.

Asbestos claims are a more recent challenge for J&J. It won the only other asbestos-related trial in November when a Los Angeles Superior Court jury ruled in its favour.

  • Related Posts

    Probe report into maternal deaths sparks Kota row

    Rajasthan Health Minister Gajendra Singh Khinvsar confirmed that government has received the report and is conducting a review JAIPUR: The report of the probe into the deaths of five pregnant women…

    Centre bans 16 Fixed-Dose Combination drugs over safety concerns

    The Centre has imposed an immediate ban on 16 Fixed Dose Combination (FDC) drugs. The Ministry of Health and Family Welfare issued the orders under Section 26A of the Drugs…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Probe report into maternal deaths sparks Kota row

    Probe report into maternal deaths sparks Kota row

    Centre bans 16 Fixed-Dose Combination drugs over safety concerns

    Centre bans 16 Fixed-Dose Combination drugs over safety concerns

    Maha FDA seizes medicines worth Rs 9.09 lakh from Mumbai children’s hospital over alleged illegal sale

    Maha FDA seizes medicines worth Rs 9.09 lakh from Mumbai children’s hospital over alleged illegal sale

    CDSCO constitutes consultancy committee for advice on suo motu disclosure

    CDSCO constitutes consultancy committee for advice on suo motu disclosure

    Telangana DCA busts illegal API stock, seizes drugs worth Rs 34L

    Telangana DCA busts illegal API stock, seizes drugs worth Rs 34L

    Zenré Wellness, a New Genre of Mental Care, unveils in Delhi

    Zenré Wellness, a New Genre of Mental Care, unveils in Delhi